DRREDDYDr. Reddy's Laboratories
Pharma · Pharmaceuticals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Dr. Reddy's Laboratories operates in the Pharmaceuticals space within the Pharma sector.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on DRREDDY — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.19
- • Valuation vs sector: P/E 29.4 vs sector 40.5
- • PEG ratio: 1.60
- • MACD: fresh bullish crossover
- • Trend strength (ADX): 31
- • Volume: 2.0x 20-day average
Bull case
- • Debt/Equity: 0.19
- • Valuation vs sector: P/E 29.4 vs sector 40.5
- • PEG ratio: 1.60
- • MACD: fresh bullish crossover
Bear case
- • Revenue growth: -5.6% YoY
- • Profit growth: -68.7% YoY
- • Price vs EMA21: below
- • Price vs SMA50: below
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -5.6% YoY
- • Profit growth: -68.7% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹21.23). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.